Cipla’s arm inks definitive agreement for acquisition of 100% stake in Duomed

09 Apr 2015 Evaluate

Cipla’s wholly owned subsidiary - Cipla (EU), UK, has entered into a definitive agreement for acquisition of 100% stake in Duomed Produtos Farmaceuticos (Duomed), a limited liability Company in Brazil for a cash consideration of Brazilian Real 1,293,600 approximately Rs 2.6 crore.

Duomed was incorporated on June 10, 2013. It has in place approval of ANVISA (Brazilian health authority) and other regulatory authorities to import and distribute pharmaceutical products in Brazil. The acquisition is part of company’s front-end strategy and will expedite its product registrations in Brazil. The transaction is expected to be completed by end of May 2015, subject to certain closing deliverables.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally.


Cipla Share Price

1520.55 -0.65 (-0.04%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×